Payment overview · 2025
General Payments
$405.41
22 reported records · 15 companies
Healthcare provider profile · identity verified
James D Quarles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKFORT, KY · NPI 1629077326
Verified facts
What the public records show
CMS Open Payments records show James D Quarles, MD received $405.41 in general payments during 2025 across 22 reported records.
GlaxoSmithKline, LLC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 748 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.21 | 15.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.76 | 11.5% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $46.39 | 11.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.99 | 8.1% | 2 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $31.73 | 7.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.90 | 7.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.48 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.96 | 5.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.17 | 4.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.90 | 4.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.42 | 4.0% | 1 | 2025 |
| Digestive Care, Inc. | Unresolved — no canonical attribution shown | $16.02 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.16 | 3.7% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.57 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.75 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.41 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.21 | 3 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Pertzye Normalized: pertzye |
Drug | Digestive Care, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 748 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
748 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 921 | 134 |
| Eliquis | Apixaban | 748 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 154 |
| Gabapentin | Gabapentin | 538 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 102 |
| Omeprazole | Omeprazole | 401 | 108 |
| Furosemide | Furosemide | 377 | 69 |
| Trazodone Hcl | Trazodone Hcl | 367 | 59 |
| Metformin Hcl | Metformin Hcl | 354 | 70 |
| Famotidine | Famotidine | 352 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 325 | 59 |
| Potassium Chloride | Potassium Chloride | 313 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 296 | 51 |
| Carvedilol | Carvedilol | 280 | 63 |
| Buspirone Hcl | Buspirone Hcl | 275 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 273 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 261 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 53 |
| Sertraline Hcl | Sertraline Hcl | 254 | 52 |
| Lisinopril | Lisinopril | 252 | 55 |
| Donepezil Hcl | Donepezil Hcl | 247 | 41 |
| Levetiracetam | Levetiracetam | 246 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 43 |
| Divalproex Sodium | Divalproex Sodium | 214 | 32 |
| Losartan Potassium | Losartan Potassium | 212 | 48 |
| Tramadol Hcl | Tramadol Hcl | 199 | 49 |
| Lorazepam | Lorazepam | 196 | 28 |
| Mirtazapine | Mirtazapine | 196 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 30 |
| Xarelto | Rivaroxaban | 163 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 158 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 30 |
| Bumetanide | Bumetanide | 151 | 33 |
| Memantine Hcl | Memantine Hcl | 148 | 26 |
| Alprazolam | Alprazolam | 147 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 132 | 48 |
| Prednisone | Prednisone | 132 | 65 |
| Lactulose | Lactulose | 125 | 20 |
| Ondansetron Odt | Ondansetron | 113 | 55 |
| Montelukast Sodium | Montelukast Sodium | 112 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 24 |
| Baclofen | Baclofen | 106 | 20 |
| Entresto | Sacubitril/Valsartan | 103 | 15 |
| Clonazepam | Clonazepam | 102 | 16 |
| Simvastatin | Simvastatin | 102 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 14 |
| Jardiance | Empagliflozin | 100 | 12 |
| Linzess | Linaclotide | 99 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 92 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 14 |
| Ezetimibe | Ezetimibe | 89 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 88 | 20 |
| Januvia | Sitagliptin Phosphate | 87 | 18 |
| Ozempic | Semaglutide | 87 | 19 |
| Azithromycin | Azithromycin | 86 | 54 |
| Allopurinol | Allopurinol | 83 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 36 |
| Nystatin | Nystatin | 76 | 36 |
| Finasteride | Finasteride | 70 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 11 |
| Valsartan | Valsartan | 70 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 24 |
| Methenamine Hippurate | Methenamine Hippurate | 68 | 12 |
| Spironolactone | Spironolactone | 68 | 22 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 57 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 26 |
| Nifedipine Er | Nifedipine | 62 | suppressed |
| Risperidone | Risperidone | 62 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 41 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Pregabalin | Pregabalin | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | suppressed |
| Fenofibrate | Fenofibrate | 56 | 17 |
| Meclizine Hcl | Meclizine Hcl | 55 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Diazepam | Diazepam | 52 | suppressed |
| Latanoprost | Latanoprost | 52 | 13 |
| Methocarbamol | Methocarbamol | 52 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 50 | suppressed |
| Glimepiride | Glimepiride | 50 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Lacosamide | Lacosamide | 49 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 49 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 12 |
| Cephalexin | Cephalexin | 48 | 26 |
| Meloxicam | Meloxicam | 48 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 32 |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Cefdinir | Cefdinir | 44 | 29 |
| Celecoxib | Celecoxib | 44 | 14 |
| Methylprednisolone | Methylprednisolone | 43 | 37 |
| Midodrine Hcl | Midodrine Hcl | 43 | 20 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 39 | 15 |
| Farxiga | Dapagliflozin Propanediol | 39 | 12 |
| Fluconazole | Fluconazole | 39 | 25 |
| Topiramate | Topiramate | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 27 |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Mupirocin | Mupirocin | 37 | 14 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Torsemide | Torsemide | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Xtampza Er | Oxycodone Myristate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 20 |
| Estradiol | Estradiol | 29 | 12 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Novolog | Insulin Aspart | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Acetylcysteine | Acetylcysteine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 12 |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Klayesta | Nystatin | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | 12 |
| Gemtesa | Vibegron | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Xtandi | Enzalutamide | 15 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.41 · 22 records | GlaxoSmithKline, LLC. | Andembry, Auvelity, CYCLOSET, ELIQUIS, EVENITY, Flexitouch Plus, KISUNLA, Kerendia, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, OTEZLA, Ozempic, Pertzye, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error